The Defense Advanced Research Projects Agency will conduct a Proposers Day through webcast on March 20 to discuss a program that aims to give first responders a longer window of opportunity to treat severely injured service members.
DARPA said Thursday the Biostasis program will use molecular biology to slow down biochemical reactions and delay system collapse following a traumatic injury or acute infection.
Tristan McClure-Begley, the Biostasis program manager, said the program seeks to control molecular machines that catalyze biochemical reactions and slow them down in a way that would not have negative effects when intervention is reversed or stopped.
The program will explore various approaches that will scale from antibodies to whole cells and tissues, and eventually to a whole organism.
Researchers will perform work under Biostasis over a five-year period, with a goal of creating proof-of-concept technologies that will be tested on simple living systems
DARPA will coordinate with federal health and regulatory agencies to support the future use of Biostasis tools on patients.